Tech Company Financing Transactions
Vivaldi BioSciences Funding Round
Vivaldi BioSciences, based in Fort Collins, received $2 million from Bay City Capital, NGN Capital and private investors.
Transaction Overview
Company Name
Announced On
9/30/2010
Transaction Type
Venture Equity
Amount
$1,975,200
Round
Undisclosed
Investors
Bay City Capital (William Gerber)
NGN Capital (Peter Johann)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3185-A Rampart Rd. 0922
Fort Collins, CO 80523
USA
Fort Collins, CO 80523
USA
Phone
Website
Email Address
Overview
Vivaldi Biosciences Inc. is developing genetically engineered vaccines with the potential for increased effectiveness in the prevention of common seasonal influenza ("flu") and emergent pandemic flu.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Wick
Chief Scientific Officer
Thomas Muster
VP - Manufacturing
Manfred Reiter
Browse more venture capital transactions:
Prev: 9/30/2010: Radiate Media venture capital transaction
Next: 9/30/2010: BirdDog Solutions venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs